SCHEMBL2037671

SCHEMBL2037671

CCCCCOC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 3/20 0.42
TSHR P16473 4/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
EPHX1 P07099 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
PRKCA P17252 1/20 0.38
HCAR2 Q8TDS4 2/20 0.38
MMP1 P03956 1/20 0.37
MMP9 P14780 1/20 0.37
MMP12 P39900 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22919640 0.98 NAAA (0.44) NAAATSHRTP53CYP3A4MAPK1
SCHEMBL7278773 0.98 NAAA (0.44) NAAATSHRTP53CYP3A4MAPK1
Bicarbonate SCHEMBL27875196 0.97 NAAA (0.40) NAAATSHRTP53CYP3A4MAPK1
SCHEMBL13541624 0.95 ALDH1A1 (0.42) NAAATSHRCYP3A4MAPK1ALDH1A1
SCHEMBL12903327 0.93 NAAA (0.40) NAAATSHREPHX1ALDH1A1LMNA
SCHEMBL9927889 0.90 FAAH (0.46) LMNAPRKCA
SCHEMBL13748507 0.90 ALOX12 (0.38) NAAATSHRCYP3A4ALDH1A1PRKCA
SCHEMBL1949595 0.90 ALOX12 (0.38) NAAATSHRCYP3A4ALDH1A1PRKCA
SCHEMBL863059 0.90 KMT2A (0.41) NAAATSHREPHX1ALDH1A1LMNA
SCHEMBL5821258 0.90 KMT2A (0.41) NAAATSHREPHX1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113924124-A Physiologically active substance bound to biotin moiety and composition for oral administration comprising the same D&D制药技术股份有限公司 2022-01-11 CN claimed
US-10653709-B2 Methods of folding a graft copolymer with dual anticancer drugs and related applications NORTH CAROLINA STATE UNIVERSITY (US) 2020-05-19 US claimed
US-20170080098-A1 METHODS OF FOLDING A GRAFT COPOLYMER WITH DUAL ANTICANCER DRUGS AND RELATED APPLICATIONS NORTH CAROLINA STATE UNIVERSITY (US) 2017-03-23 US claimed
WO-2015179402-A1 METHODS OF FOLDING A GRAFT COPOLYMER WITH DUAL ANTICANCER DRUGS AND RELATED APPLICATIONS NORTH CAROLINA STATE UNIVERSITY (US) 2015-11-26 WO claimed
JP-2006522140-A 2006-09-28 JP claimed
EP-1608380-A2 POLYMERIC DRUG AGENTS FOR THE TREATMENT OF FIBROTIC DISORDERS Vectramed, Inc. (US) 2005-12-28 EP claimed
WO-2004089311-A2 POLYMERIC DRUG AGENTS FOR THE TREATMENT OF FIBROTIC DISORDERS VECTRAMED, INC. (US) 2004-10-21 WO claimed
US-6759170-B2 Organic carbonate additives for nonaqueous electrolyte rechargeable electrochemical cells WILSON GREATBATCH TECHNOLOGIES, INC. 2004-07-06 US claimed
EP-1158589-A1 SECONDARY LITHIUM BATTERY, NEGATIVE ELECTRODE FOR SECONDARY LITHIUM BATTERY, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE FUJITSU LIMITED (JP) 2001-11-28 EP claimed
EP-0803924-B1 Organic carbonate additives for nonaqueous electrolyte in alkali metal electrochemical cells GREATBATCH W LTD (US) 2001-10-31 EP claimed
US-20010031396-A1 Lithium secondary battery, anode for lithium secondary battery, and method for manufacturing the anode FUJITSU LIMITED (JP) 2001-10-18 US claimed
EP-0996187-A1 Organic carbonate additives for nonaqueous electrolyte rechargeable cells WILSON GREATBATCH LTD. (US) 2000-04-26 EP claimed
EP-0803924-A2 Organic carbonate additives for nonaqueous electrolyte in alkali metal electrochemical cells WILSON GREATBATCH LTD. (US) 1997-10-29 EP claimed
US-11894518-B2 Electrolytes for stable cycling of high capacity lithium based batteries IONBLOX, INC. 2024-02-06 US disclosed
CN-113924124-A Physiologically active substance bound to biotin moiety and composition for oral administration comprising the same D&D制药技术股份有限公司 2022-01-11 CN disclosed
US-20210376383-A1 ELECTROLYTES FOR STABLE CYCLING OF HIGH CAPACITY LITHIUM BASED BATTERIES IONBLOX, INC. 2021-12-02 US disclosed
EP-1158589-A1 SECONDARY LITHIUM BATTERY, NEGATIVE ELECTRODE FOR SECONDARY LITHIUM BATTERY, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE FUJITSU LIMITED (JP) 2001-11-28 EP disclosed
US-20010031396-A1 Lithium secondary battery, anode for lithium secondary battery, and method for manufacturing the anode FUJITSU LIMITED (JP) 2001-10-18 US disclosed
WO-2000064486-A2 ENZYMATICALLY ACTIVATED POLYMERIC DRUG CONJUGATES VECTRAMED, INC. (US) 2000-11-02 WO disclosed
US-5998065-A N-OXYIMIDE ADDITIVE FUJITSU LIMITED (JP) 1999-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170080098-A1 METHODS OF FOLDING A GRAFT COPOLYMER WITH DUAL ANTICANCER DRUGS AND RELATED APPLICATIONS MCL1, BCL2L1, PDIA6 NAAA 2601/4885TSHR 4556/4885TP53 28/4885
US-10653709-B2 Methods of folding a graft copolymer with dual anticancer drugs and related applications MCL1, BCL2L1, PDIA6 NAAA 2601/4885TSHR 4556/4885TP53 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.